ELAC2 and prostate carcinoma: Transformants were plated onto FOA to select against the TRZ1 expression plasmid and to determine if any construct could complement trz1. As shown in Table 4, neither wild type nor prostate cancer-associated ELAC2 mutants could substitute for wild type TRZ1 function in YL03-47.